Conversion Therapy for Advanced Penile Cancer with Tislelizumab Combined with Chemotherapy: A Case Report and Review of Literature

Overview

Journal World J Clin Cases

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2022 Dec 9

PMID 36483823

Authors

Xiang-Yu Long

Shuang Zhang

Lian-Sha Tang

Xiang Li

Ji-Yan Liu

Affiliations

Soon will be listed here.

Abstract

Background: Locally advanced penile squamous cell carcinoma with unresectable inguinal lymph node metastasis has a poor prognosis, and surgical treatment alone offers limited benefits. Effective conversion therapy regimens are urgently needed.

Case Summary: We describe a locally advanced penile squamous cell carcinoma patient with bulky, fixed inguinal lymph node metastasis complicated with genital skin ulcers who underwent inguinal lymph node dissection and achieved a pathological complete response with conversion therapy comprising immunotherapy plus chemotherapy.

Conclusion: For unresectable locally advanced penile squamous cell carcinoma, neoadjuvant immunotherapy combined with chemotherapy is a potential treatment approach. Biomarkers of immunotherapy efficacy need to be explored, and clinical trials are needed to test these strategies.

Citing Articles

Evidence-Based Recommendations on the Use of Immunotherapies and Monoclonal Antibodies in the Treatment of Male Reproductive Cancers.

Khalid F, Bodla Z, Gaddameedi S, Macasaet R, Yagnik K, Niaz Z Curr Oncol. 2025; 32(2).

PMID: 39996908 PMC: 11854063. DOI: 10.3390/curroncol32020108.

Programmed death‑ligand 1 expression in tumor cells and tumor‑infiltrating lymphocytes are associated with depth of tumor invasion in penile cancer.

Sangkhamanon S, Kotano N, Sirithanaphol W, Rompsaithong U, Kiatsopit P, Sookprasert A Biomed Rep. 2023; 19(1):44.

PMID: 37324166 PMC: 10265570. DOI: 10.3892/br.2023.1627.

References

Dillner J, von Krogh G, Horenblas S, Meijer C . Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl. 2001; (205):189-93. DOI: 10.1080/00365590050509913. View

Ottenhof S, Djajadiningrat R, Thygesen H, Jakobs P, Jozwiak K, Heeren A . The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma. Front Immunol. 2018; 9:1253. PMC: 6004546. DOI: 10.3389/fimmu.2018.01253. View

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S . PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009; 69(5):1851-7. DOI: 10.1158/0008-5472.CAN-08-2466. View

Ali S, Pal S, Wang K, Palma N, Sanford E, Bailey M . Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations. Oncologist. 2015; 21(1):33-9. PMC: 4709208. DOI: 10.1634/theoncologist.2015-0241. View

Paz Rojas J, Ballestas Almario C, Garcia-Perdomo H . Effectiveness and safety of adjuvant chemotherapy compared to neoadjuvant chemotherapy in patients with penile cancer and positive lymph nodes regarding overall survival and free disease survival: a systematic review and meta-analysis. Urol Oncol. 2022; 40(5):200.e11-200.e18. DOI: 10.1016/j.urolonc.2022.02.014. View

Keung E, Ukponmwan E, Cogdill A, Wargo J . The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. Ann Surg Oncol. 2018; 25(7):1814-1827. PMC: 6105272. DOI: 10.1245/s10434-018-6379-8. View

Pandey D, Mahajan V, Kannan R . Prognostic factors in node-positive carcinoma of the penis. J Surg Oncol. 2006; 93(2):133-8. DOI: 10.1002/jso.20414. View

Chan T, Yarchoan M, Jaffee E, Swanton C, Quezada S, Stenzinger A . Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2018; 30(1):44-56. PMC: 6336005. DOI: 10.1093/annonc/mdy495. View

10.

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

11.

Forde P, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad M . Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022; 386(21):1973-1985. PMC: 9844511. DOI: 10.1056/NEJMoa2202170. View

12.

Paijens S, Vledder A, de Bruyn M, Nijman H . Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2020; 18(4):842-859. PMC: 8115290. DOI: 10.1038/s41423-020-00565-9. View

13.

Mamdani H, Matosevic S, Khalid A, Durm G, Jalal S . Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Front Immunol. 2022; 13:823618. PMC: 8864096. DOI: 10.3389/fimmu.2022.823618. View

14.

Ahmed M, Falasiri S, Hajiran A, Chahoud J, Spiess P . The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy. J Clin Med. 2020; 9(10). PMC: 7603091. DOI: 10.3390/jcm9103334. View

15.

Philippou P, Shabbir M, Malone P, Nigam R, Muneer A, Ralph D . Conservative surgery for squamous cell carcinoma of the penis: resection margins and long-term oncological control. J Urol. 2012; 188(3):803-8. DOI: 10.1016/j.juro.2012.05.012. View

16.

Minhas S, Manseck A, Watya S, Hegarty P . Penile cancer--prevention and premalignant conditions. Urology. 2010; 76(2 Suppl 1):S24-35. DOI: 10.1016/j.urology.2010.04.007. View

17.

Weber J, DAngelo S, Minor D, Hodi F, Gutzmer R, Neyns B . Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16(4):375-84. DOI: 10.1016/S1470-2045(15)70076-8. View

18.

Wang J, Zhu Y, Tang S, Zhang H, Qin X, Zhang S . Prognostic significance of the degree of extranodal extension in patients with penile carcinoma. Asian J Androl. 2014; 16(3):437-41. PMC: 4023374. DOI: 10.4103/1008-682X.122862. View

19.

Olesen T, Sand F, Rasmussen C, Albieri V, Toft B, Norrild B . Prevalence of human papillomavirus DNA and p16 in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol. 2018; 20(1):145-158. DOI: 10.1016/S1470-2045(18)30682-X. View

20.

Tarhini A, Eads J, Moore K, Tatard-Leitman V, Wright J, Forde P . Neoadjuvant immunotherapy of locoregionally advanced solid tumors. J Immunother Cancer. 2022; 10(8). PMC: 9386211. DOI: 10.1136/jitc-2022-005036. View